141 related articles for article (PubMed ID: 27012810)
21. Tamoxifen-induced severe hot flashes and endoxifen levels: is dose reduction a safe and effective strategy?
Lee CI; Fox P; Balakrishnar B; Balleine RL; Gao B; Provan P; Coulter S; Liddle C; Hui R; Wong M; Gurney H; Wilcken N
Breast; 2019 Aug; 46():52-57. PubMed ID: 31082762
[TBL] [Abstract][Full Text] [Related]
22. The effect of rs5758550 on CYP2D6*2 phenotype and formation of endoxifen in breast cancer patients using tamoxifen.
Sanchez-Spitman AB; Moes DA; Gelderblom H; Dezentjé VO; Swen JJ; Guchelaar HJ
Pharmacogenomics; 2017 Aug; 18(12):1125-1132. PubMed ID: 28745555
[TBL] [Abstract][Full Text] [Related]
23. Multigene and Drug Interaction Approach for Tamoxifen Metabolite Patterns Reveals Possible Involvement of CYP2C9, CYP2C19, and ABCB1.
Powers JL; Buys SS; Fletcher D; Melis R; Johnson-Davis KL; Lyon E; Malmberg EM; McMillin GA
J Clin Pharmacol; 2016 Dec; 56(12):1570-1581. PubMed ID: 27198207
[TBL] [Abstract][Full Text] [Related]
24. Sequential or concurrent tamoxifen and radiotherapy: to see or not to see--that is the question!
Bentzen SM; Yarnold JR
J Clin Oncol; 2005 Sep; 23(25):6266-7; author reply 6267. PubMed ID: 16135499
[No Abstract] [Full Text] [Related]
25. A preliminary study on the association of tamoxifen, endoxifen, and 4-hydroxytamoxifen with blood lipids in patients with breast cancer.
Siqueira MLS; Andrade SMV; Vieira JLF; Monteiro MC
Biomed Pharmacother; 2021 Oct; 142():111972. PubMed ID: 34391185
[TBL] [Abstract][Full Text] [Related]
26. An Antiestrogenic Activity Score for tamoxifen and its metabolites is associated with breast cancer outcome.
de Vries Schultink AH; Alexi X; van Werkhoven E; Madlensky L; Natarajan L; Flatt SW; Zwart W; Linn SC; Parker BA; Wu AH; Pierce JP; Huitema AD; Beijnen JH
Breast Cancer Res Treat; 2017 Feb; 161(3):567-574. PubMed ID: 28005246
[TBL] [Abstract][Full Text] [Related]
27. A Pharmacokinetic-Pharmacodynamic Model of Tamoxifen and Endoxifen to Predict Their Distribution and Effects on Inhibition of Tumor Growth.
Yuan S; Sun Q; Chen Y; Liao J
Drug Metab Lett; 2017; 11(2):93-101. PubMed ID: 28814243
[TBL] [Abstract][Full Text] [Related]
28. Rationale for sequential tamoxifen and anticancer drugs in adjuvant setting for patients with node- and receptor-positive breast cancer.
Kim R; Tanabe K; Emi M; Uchida Y; Osaki A; Toge T
Int J Oncol; 2005 Apr; 26(4):1025-31. PubMed ID: 15753998
[TBL] [Abstract][Full Text] [Related]
29. The development of endoxifen for breast cancer.
Goetz MP
Clin Adv Hematol Oncol; 2018 Feb; 16(2):102-105. PubMed ID: 29741509
[No Abstract] [Full Text] [Related]
30. Targeting of tamoxifen to enhance antitumour action for the treatment and prevention of breast cancer: the 'personalised' approach?
Brauch H; Jordan VC
Eur J Cancer; 2009 Sep; 45(13):2274-83. PubMed ID: 19592233
[TBL] [Abstract][Full Text] [Related]
31. Tamoxifen for early breast cancer: better late than never.
Gray R; Davies C; Perry P
Ann Oncol; 2000 May; 11(5):505-7. PubMed ID: 10907940
[No Abstract] [Full Text] [Related]
32. New insights into the metabolism of tamoxifen and its role in the treatment and prevention of breast cancer.
Jordan VC
Steroids; 2007 Nov; 72(13):829-42. PubMed ID: 17765940
[TBL] [Abstract][Full Text] [Related]
33. Tamoxifen for breast cancer.
Karn A; Jha AK; Shrestha S; Acharya B; Poudel S; Bhandari RB
JNMA J Nepal Med Assoc; 2010; 49(177):62-7. PubMed ID: 21180225
[TBL] [Abstract][Full Text] [Related]
34. Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen.
Lim YC; Desta Z; Flockhart DA; Skaar TC
Cancer Chemother Pharmacol; 2005 May; 55(5):471-8. PubMed ID: 15685451
[TBL] [Abstract][Full Text] [Related]
35. Neoadjuvant endocrine therapy for breast cancer: more questions than answers.
Ellis MJ
J Clin Oncol; 2005 Aug; 23(22):4842-4. PubMed ID: 15998901
[No Abstract] [Full Text] [Related]
36. Cytochrome P-450 2D6 (CYP2D6) Genotype and Breast Cancer Recurrence in Tamoxifen-Treated Patients: Evaluating the Importance of Loss of Heterozygosity.
Ahern TP; Hertz DL; Damkier P; Ejlertsen B; Hamilton-Dutoit SJ; Rae JM; Regan MM; Thompson AM; Lash TL; Cronin-Fenton DP
Am J Epidemiol; 2017 Jan; 185(2):75-85. PubMed ID: 27988492
[TBL] [Abstract][Full Text] [Related]
37. Variation in use of adjuvant tamoxifen.
Davies C; McGale P; Peto R
Lancet; 1998 May; 351(9114):1487-8. PubMed ID: 9605808
[No Abstract] [Full Text] [Related]
38. Efficacy of tamoxifen as treatment of breast cancer.
Powles TJ
Semin Oncol; 1997 Feb; 24(1 Suppl 1):S1-48-S1-54. PubMed ID: 9045315
[TBL] [Abstract][Full Text] [Related]
39. The Effect of Tamoxifen Dose Increment in Patients With Impaired CYP2D6 Activity.
Welzen ME; Dezentjé VO; van Schaik RH; Colbers AP; Guchelaar HJ; van Erp NP; den Hartigh J; Burger DM; van Laarhoven HW
Ther Drug Monit; 2015 Aug; 37(4):501-7. PubMed ID: 26192892
[TBL] [Abstract][Full Text] [Related]
40. Toxicity and adverse effects of Tamoxifen and other anti-estrogen drugs.
Yang G; Nowsheen S; Aziz K; Georgakilas AG
Pharmacol Ther; 2013 Sep; 139(3):392-404. PubMed ID: 23711794
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
